Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma

PURPOSE: Isocitrate dehydrogenase (IDH) 1 and IDH2 mutations (IDH1/2mt) are frequent in glioma. Preclinical studies suggest IDH1/2mts confer “BRCAness” phenotype, a vulnerability that can be targeted through PARP inhibition. To test this hypothesis, we conducted a multicenter study of olaparib monot...

Descripción completa

Detalles Bibliográficos
Autores principales: Fanucci, Kristina, Pilat, Mary Jo, Shyr, Derek, Shyr, Yu, Boerner, Scott, Li, Jing, Durecki, Diane, Drappatz, Jan, Puduvalli, Vinay, Lieberman, Frank Scott, Gonzalez, Javier, Giglio, Pierre, Ivy, S. Percy, Bindra, Ranjit S., Omuro, Antonio, LoRusso, Patricia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035510/
https://www.ncbi.nlm.nih.gov/pubmed/36968138
http://dx.doi.org/10.1158/2767-9764.CRC-22-0436

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035510/
https://www.ncbi.nlm.nih.gov/pubmed/36968138
http://dx.doi.org/10.1158/2767-9764.CRC-22-0436

Ejemplares similares